Association of Fusobacterium nucleatum with immunity and molecular alterations in colorectal cancer

Table 1 Clinical and molecular features in Japanese patients with colorectal cancer according to Fusobacterium nucleatum status n (%)

Clinical and molecular features	Total (n)	F. nucleatum expression
		Negative	Positive	P-value
All cases	511	467 (91)	44 (8.6)
Gender
Male	286 (56)	267 (57)	19 (43)	0.075
Female	225 (44)	200 (43)	25 (57)
Age (mean ± SD)	67.1 ± 11.8	67.3 ± 11.7	65.0 ± 12.1	0.220
Tumor size (mm) (mean ± SD)	49.8 ± 24.1	49.2 ± 24.5	56.4 ± 19.6	0.063
Tumor location
Rectum	207 (41)	194 (42)	13 (30)
Distal colon	133 (26)	121 (26)	12 (27)	0.240
(Sigmoid colon to splenic flexure)
Proximal colon	171 (33)	152 (33)	19 (43)
(Transverse colon to cecum)
Disease stage
I	56 (11)	53 (11)	3 (6.8)	0.470
II	160 (31)	142 (30)	18 (41)
III	235 (46)	216 (46)	19 (43)
IV	60 (12)	56 (12)	4 (9.0)
KRAS mutation (codon 12/13/61/146)
Wild-type	354 (69)	324 (69)	30 (68)	0.870
Mutant	157 (31)	143 (31)	14 (32)
BRAF mutation (codon 600)
Wild-type	483 (95)	445 (95)	38 (86)	0.031
Mutant	28 (5.5)	22 (4.7)	6 (14)
PIK3CA mutation (exon 9/20)
Wild-type	451 (88)	414 (89)	37 (84)	0.390
Mutant	60 (12)	53 (11)	7 (16)
MSI status
MSS/MSI-low	470 (92)	435 (93)	35 (80)	0.0059
MSI-high	41 (8.0)	32 (6.9)	9 (20)

Percentage (%) indicates the proportion of cases with a specific clinical or molecular feature within a given category of F. nucleatum detection by quantitative PCR. The P-values were calculated using t-test for age and tumor size and by means of the χ² test or Fisher’s exact test for all other variables. F. nucleatum: Fusobacterium nucleatum; MSI: Microsatellite instability; MSS: Microsatellite stable.